ArticleSurgical case reports2026
Pancreaticoduodenectomy for Mass-Forming Localized Duodenal Amyloidosis: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLocalized duodenal amyloidosis is extremely rare, with only a few cases having been documented in the literature. To the best of our knowledge, we report the first case of localized amyloid light-chain (AL) λ-type duodenal amyloidosis diagnosed after pancreaticoduodenectomy (PD). CASE PRESENTATION: A 71-year-old asymptomatic man was referred to our hospital after plain radiography revealed a calcified mass in the upper abdomen. Contrast-enhanced CT revealed a 58-mm exophytic mass with prominent peripheral calcification on the dorsal aspect of the descending duodenum, showing continuity with the pancreatic head vasculature. Endoscopic ultrasonography (EUS) could not evaluate the internal structure because of acoustic shadowing from dense calcification, thereby precluding EUS-guided tissue acquisition. Because malignancies, including gastrointestinal stromal tumors and lymphoma, could not be excluded, a subtotal stomach-preserving PD was performed for diagnostic and therapeutic purposes. Histopathological examination revealed extensive amyloid deposition that tested positive for Congo red staining, direct fast scarlet, and λ-light chain, while showing negative staining for κ-light chain, amyloid transthyretin, and serum amyloid A, thereby establishing a diagnosis of localized ALλ-type amyloidosis. A comprehensive systemic workup, including echocardiography, cardiac MRI, serum and urine immunofixation electrophoresis, and free light chain assays, excluded systemic amyloidosis. The patient was managed with observation alone without chemotherapy and remained recurrence-free for 2 years postoperatively.
conclusionsWhen preoperative tissue diagnosis is not feasible because of extensive calcification and malignancy cannot be excluded, surgical resection, including PD, for localized ALλ-type duodenal amyloidosis should be considered as both a diagnostic and therapeutic intervention. After a diagnosis of localized amyloidosis is made, the exclusion of systemic disease and long-term follow-up are essential to monitor for local recurrence, the emergence of clonal disease, and potential progression to systemic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.